292 related articles for article (PubMed ID: 30016148)
1. Combined Analysis of Biparametric MRI and Prostate-Specific Antigen Density: Role in the Prebiopsy Diagnosis of Gleason Score 7 or Greater Prostate Cancer.
Lee SJ; Oh YT; Jung DC; Cho NH; Choi YD; Park SY
AJR Am J Roentgenol; 2018 Sep; 211(3):W166-W172. PubMed ID: 30016148
[TBL] [Abstract][Full Text] [Related]
2. Biparametric Magnetic Resonance Imaging-Derived Nomogram to Detect Clinically Significant Prostate Cancer by Targeted Biopsy for Index Lesion.
Kim MJ; Park SY
J Magn Reson Imaging; 2022 Apr; 55(4):1226-1233. PubMed ID: 34296803
[TBL] [Abstract][Full Text] [Related]
3. Prebiopsy Biparametric Magnetic Resonance Imaging Combined with Prostate-specific Antigen Density in Detecting and Ruling out Gleason 7-10 Prostate Cancer in Biopsy-naïve Men.
Boesen L; Nørgaard N; Løgager V; Balslev I; Bisbjerg R; Thestrup KC; Jakobsen H; Thomsen HS
Eur Urol Oncol; 2019 May; 2(3):311-319. PubMed ID: 31200846
[TBL] [Abstract][Full Text] [Related]
4. Risk Stratification Among Men With Prostate Imaging Reporting and Data System version 2 Category 3 Transition Zone Lesions: Is Biopsy Always Necessary?
Felker ER; Raman SS; Margolis DJ; Lu DSK; Shaheen N; Natarajan S; Sharma D; Huang J; Dorey F; Marks LS
AJR Am J Roentgenol; 2017 Dec; 209(6):1272-1277. PubMed ID: 28858541
[TBL] [Abstract][Full Text] [Related]
5. Prebiopsy multiparametric MRI and PI-RADS version 2.0 for differentiating histologically benign prostate disease from prostate cancer in biopsies: A retrospective single-center comparison.
Tosun M; Uslu H
Clin Imaging; 2021 Oct; 78():98-103. PubMed ID: 33773450
[TBL] [Abstract][Full Text] [Related]
6. Analysis of risk factors for determining the need for prostate biopsy in patients with negative MRI.
Liang L; Qi F; Cheng Y; Zhang L; Cao D; Cheng G; Hua L
Sci Rep; 2021 Mar; 11(1):6048. PubMed ID: 33723287
[TBL] [Abstract][Full Text] [Related]
7. Role of PI-RADS Version 2 for Prediction of Upgrading in Biopsy-Proven Prostate Cancer With Gleason Score 6.
Song W; Bang SH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Choi HY; Kim CK; Lee HM
Clin Genitourin Cancer; 2018 Aug; 16(4):281-287. PubMed ID: 29550198
[TBL] [Abstract][Full Text] [Related]
8. The performance of PI-RADSv2 and quantitative apparent diffusion coefficient for predicting confirmatory prostate biopsy findings in patients considered for active surveillance of prostate cancer.
Nougaret S; Robertson N; Golia Pernicka J; Molinari N; Hötker AM; Ehdaie B; Sala E; Hricak H; Vargas HA
Abdom Radiol (NY); 2017 Jul; 42(7):1968-1974. PubMed ID: 28258355
[TBL] [Abstract][Full Text] [Related]
9. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
[No Abstract] [Full Text] [Related]
10. Prebiopsy IMPROD Biparametric Magnetic Resonance Imaging Combined with Prostate-Specific Antigen Density in the Diagnosis of Prostate Cancer: An External Validation Study.
Knaapila J; Jambor I; Perez IM; Ettala O; Taimen P; Verho J; Kiviniemi A; Pahikkala T; Merisaari H; Lamminen T; Saunavaara J; Aronen HJ; Syvänen KT; Boström PJ
Eur Urol Oncol; 2020 Oct; 3(5):648-656. PubMed ID: 31501082
[TBL] [Abstract][Full Text] [Related]
11. MRI combined with PSA density in detecting clinically significant prostate cancer in patients with PSA serum levels of 4∼10ng/mL: Biparametric versus multiparametric MRI.
Han C; Liu S; Qin XB; Ma S; Zhu LN; Wang XY
Diagn Interv Imaging; 2020 Apr; 101(4):235-244. PubMed ID: 32063483
[TBL] [Abstract][Full Text] [Related]
12. Clinically Significant Prostate Cancer Detection After a Negative Prebiopsy MRI Examination: Comparison of Biparametric Versus Multiparametric MRI.
Gan JM; Kikano EG; Smith DA; Rao S; Podury R; Wang M; Durieux JC; Paspulati RM; Ponsky L; Ramaiya NH; Tirumani SH
AJR Am J Roentgenol; 2022 May; 218(5):859-866. PubMed ID: 34817189
[No Abstract] [Full Text] [Related]
13. Comparison of quantitative apparent diffusion coefficient parameters with prostate imaging reporting and data system V2 assessment for detection of clinically significant peripheral zone prostate cancer.
Hassanzadeh E; Alessandrino F; Olubiyi OI; Glazer DI; Mulkern RV; Fedorov A; Tempany CM; Fennessy FM
Abdom Radiol (NY); 2018 May; 43(5):1237-1244. PubMed ID: 28840280
[TBL] [Abstract][Full Text] [Related]
14. Prostate Imaging Reporting and Data System, Version 2, Assessment Categories and Pathologic Outcomes in Patients With Gleason Score 3 + 4 = 7 Prostate Cancer Diagnosed at Biopsy.
Lim CS; McInnes MDF; Flood TA; Breau RH; Morash C; Thornhill RE; Schieda N
AJR Am J Roentgenol; 2017 May; 208(5):1037-1044. PubMed ID: 28267359
[TBL] [Abstract][Full Text] [Related]
15. PI-RADS version 2 for prediction of pathological downgrading after radical prostatectomy: a preliminary study in patients with biopsy-proven Gleason Score 7 (3+4) prostate cancer.
Woo S; Kim SY; Lee J; Kim SH; Cho JY
Eur Radiol; 2016 Oct; 26(10):3580-7. PubMed ID: 26847042
[TBL] [Abstract][Full Text] [Related]
16. Values of multiparametric and biparametric MRI in diagnosing clinically significant prostate cancer: a multivariate analysis.
Feng X; Chen X; Peng P; Zhou H; Hong Y; Zhu C; Lu L; Xie S; Zhang S; Long L
BMC Urol; 2024 Feb; 24(1):40. PubMed ID: 38365673
[TBL] [Abstract][Full Text] [Related]
17. Combining Magnetic Resonance Diffusion-Weighted Imaging with Prostate-Specific Antigen to Differentiate Between Malignant and Benign Prostate Lesions.
Han L; He G; Mei Y; Yu Q; Zhao M; Luo F; Cheng G; Liang W
Med Sci Monit; 2022 Apr; 28():e935307. PubMed ID: 35459760
[TBL] [Abstract][Full Text] [Related]
18. Can Apparent Diffusion Coefficient Values Assist PI-RADS Version 2 DWI Scoring? A Correlation Study Using the PI-RADSv2 and International Society of Urological Pathology Systems.
Gaur S; Harmon S; Rosenblum L; Greer MD; Mehralivand S; Coskun M; Merino MJ; Wood BJ; Shih JH; Pinto PA; Choyke PL; Turkbey B
AJR Am J Roentgenol; 2018 Jul; 211(1):W33-W41. PubMed ID: 29733695
[TBL] [Abstract][Full Text] [Related]
19. Optimizing prostate cancer accumulating model: combined PI-RADS v2 with prostate specific antigen and its derivative data.
Lu YF; Zhang Q; Yao WG; Chen HY; Chen JY; Xu CC; Yu RS
Cancer Imaging; 2019 May; 19(1):26. PubMed ID: 31122297
[TBL] [Abstract][Full Text] [Related]
20. Prebiopsy biparametric MRI: differences of PI-RADS version 2 in patients with different PSA levels.
Choi MH; Lee YJ; Jung SE; Rha SE; Byun JY
Clin Radiol; 2018 Sep; 73(9):810-817. PubMed ID: 29895386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
